FDA — authorised 27 September 2024
- Application: NDA215168
- Marketing authorisation holder: GE HLTHCARE
- Local brand name: FLYRCADO
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
🇺🇸 Flyrcado in United States
FDA authorised Flyrcado on 27 September 2024
Marketing authorisations
FDA
- Marketing authorisation holder: GE HLTHCARE
- Status: approved
Flyrcado in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in United States
Frequently asked questions
Is Flyrcado approved in United States?
Yes. FDA authorised it on 27 September 2024; FDA has authorised it.
Who is the marketing authorisation holder for Flyrcado in United States?
GE HLTHCARE holds the US marketing authorisation.